D. Brockstedt

发表

Killed but metabolically active microbes: a new vaccine paradigm for eliciting effector T-cell responses and protective immunity

J. Hearst, H. Bouwer, M. Giedlin, 2005, Nature Medicine.

Attenuated Listeria monocytogenes vectors overcome suppressive plasma factors during HIV infection to stimulate myeloid dendritic cells to promote adaptive immunity and reactivation of latent virus.

N. Bhardwaj, N. Landau, P. Lauer, 2015, AIDS research and human retroviruses.

Systemic Tolerance Mediated by Melanoma Brain Tumors Is Reversible by Radiotherapy and Vaccination

Christopher M. Jackson, J. Taube, P. Calabresi, 2015, Clinical Cancer Research.

Clinical development of Listeria monocytogenes-based immunotherapies.

D. Le, D. Brockstedt, Thomas W Dubenksy, 2012, Seminars in oncology.

Interplay between CD8α+ Dendritic Cells and Monocytes in Response to Listeria monocytogenes Infection Attenuates T Cell Responses

L. Fong, D. Brockstedt, D. Kapadia, 2011, PloS one.

Priming and Activation of Human Ovarian and Breast Cancer-specific CD8+ T Cells by Polyvalent Listeria monocytogenes-based Vaccines

A. Secord, M. Giedlin, M. Morse, 2009, Journal of immunotherapy.

Impact of Preexisting Vector-Specific Immunity on Vaccine Potency: Characterization of Listeria monocytogenes-Specific Humoral and Cellular Immunity in Humans and Modeling Studies Using Recombinant Vaccines in Mice

J. Hampl, D. Brockstedt, K. Bahjat, 2009, Infection and Immunity.

Constitutive Activation of the PrfA Regulon Enhances the Potency of Vaccines Based on Live-Attenuated and Killed but Metabolically Active Listeria monocytogenes Strains

N. Freitag, E. Lemmens, P. Lauer, 2008, Infection and Immunity.

Promises and challenges for the development of Listeria monocytogenes-based

D. Brockstedt, T. Dubensky, Thomas W Dubensky, 2008 .

Cytosolic Entry Controls CD8+-T-Cell Potency during Bacterial Infection

D. Portnoy, S. Schoenberger, E. Lemmens, 2006, Infection and Immunity.

Induction of immunity to antigens expressed by recombinant adeno-associated virus depends on the route of administration.

E. Engleman, L. Fong, G. Kurtzman, 1999, Clinical immunology.

Listeria-based cancer vaccines that segregate immunogenicity from toxicity.

M. Giedlin, D. Portnoy, D. Brockstedt, 2004, Proceedings of the National Academy of Sciences of the United States of America.

Listeria monocytogenes as a Vaccine Vector: Virulence Attenuation or Existing Antivector Immunity Does Not Diminish Therapeutic Efficacy1

H. Bouwer, M. Giedlin, D. Higgins, 2004, The Journal of Immunology.

Safety and survival with GVAX pancreas prime and Listeria Monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer.

E. Jaffee, T. Greten, T. Crocenzi, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Introduction of soluble proteins into the MHC class I pathway by conjugation to an HIV tat peptide.

G. Nolan, J. Rothbard, D. Mitchell, 1997, Journal of immunology.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two

Manish R. Patel, Charles J. Vaske, Joe Y. Chang, 2016, Journal for Immunotherapy of Cancer.

Radiation therapy combined with Listeria monocytogenes-based cancer vaccine synergize to enhance tumor control in the B16 melanoma model

S. Gerber, E. Lord, D. Brockstedt, 2014, Oncoimmunology.

Efficacy Immunity Does Not Diminish Therapeutic Virulence Attenuation or Existing Antivector as a Vaccine Vector : Listeria monocytogenes

M. Giedlin, D. Higgins, D. Hinrichs, 2004 .

Selective targeting of antitumor immune responses with engineered live-attenuated Listeria monocytogenes.

D. Pardoll, M. Giedlin, R. Schulick, 2006, Cancer research.

Tumor-Associated Antigen Expressing Listeria monocytogenes Induces Effective Primary and Memory T-Cell Responses Against Hepatic Colorectal Cancer Metastases

B. Edil, D. Pardoll, R. Schulick, 2011, Annals of Surgical Oncology.

Results from a Phase IIb, Randomized, Multicenter Study of GVAX Pancreas and CRS-207 Compared with Chemotherapy in Adults with Previously Treated Metastatic Pancreatic Adenocarcinoma (ECLIPSE Study)

E. Jaffee, T. Crocenzi, Z. Wainberg, 2019, Clinical Cancer Research.

Results from a phase 2b, randomized, multicenter study of GVAX pancreas and CRS-207 compared to chemotherapy in adults with previously-treated metastatic pancreatic adenocarcinoma (ECLIPSE Study).

E. Jaffee, K. McDougall, Z. Wainberg, 2017 .

Clinical Response of Live-Attenuated, Listeria monocytogenes Expressing Mesothelin (CRS-207) with Chemotherapy in Patients with Malignant Pleural Mesothelioma

E. Jaffee, L. Coussens, K. McDougall, 2019, Clinical Cancer Research.

Anti-pancreatic tumor efficacy of a Listeria-based, Annexin A2-targeting immunotherapy in combination with anti-PD-1 antibodies

E. Jaffee, elliot k fishman, Victoria Kim, 2019, Journal of Immunotherapy for Cancer.

Interim safety and efficacy analysis of a phase II, randomized study of GVAX pancreas and CRS-207 immunotherapy in patients with metastatic pancreatic cancer.

E. Jaffee, T. Greten, T. Crocenzi, 2013 .

Heterologous vaccination targeting prostatic acid phosphatase (PAP) using DNA and Listeria vaccines elicits superior anti-tumor immunity dependent on CD4+ T cells elicited by DNA priming

D. McNeel, J. Sauer, P. Lauer, 2018, Oncoimmunology.

Interplay between CD8a Dendritic Cells and Monocytes in Response to Listeria monocytogenes Infection Attenuates T Cell Responses

L. Fong, D. Brockstedt, D. Kapadia, 2011 .

Cellular and genomic disease signature of peripheral blood mononuclear cells in patients with malignant pleural mesothelioma

R. Hassan, C. Whiting, C. Poulet, 2017 .

Enhanced Virus-Specific CD8+ T Cell Responses by Listeria monocytogenes-Infected Dendritic Cells in the Context of Tim-3 Blockade

J. Moorman, Cheng J. Ma, P. Lauer, 2014, PloS one.

Role of PD-1 and its ligand, B7-H1, in early fate decisions of CD8 T cells.

D. Getnet, C. Drake, Lieping Chen, 2007, Blood.

A novel series of conferences tackling the hurdles confronting the translation of novel cancer immunotherapies

F. Marincola, L. Butterfield, P. Srivastava, 2012, Journal of Translational Medicine.

Antigen delivery to early endosomes eliminates the superiority of human blood BDCA3+ dendritic cells at cross presentation

I. Mellman, Cécile Chalouni, L. Delamarre, 2013, The Journal of experimental medicine.

Vaccination for Prostate Cancer Dendritic Cell-Based Xenoantigen

E. Engleman, L. Fong, G. Strang, 2001 .

Attenuated Listeria monocytogenes reprograms M2-polarized tumor-associated macrophages in ovarian cancer leading to iNOS-mediated tumor cell lysis

P. Lizotte, S. Fiering, P. Lauer, 2014, Oncoimmunology.

Potent GCN2 Inhibitor Capable of Reversing MDSC-Driven T Cell Suppression Demonstrates In Vivo Efficacy as a Single Agent and in Combination with Anti-Angiogenesis Therapy.

D. Pookot, R. Sreenivasan, A. Ng, 2022, Journal of medicinal chemistry.

Safety and preliminary immunogenicity of JNJ-64041809, a live-attenuated, double-deleted Listeria monocytogenes-based immunotherapy, in metastatic castration-resistant prostate cancer

C. Drake, E. Antonarakis, D. McNeel, 2019, Prostate Cancer and Prostatic Diseases.

Activation of Immature Hepatic NK Cells As Immunotherapy for Liver Metastatic Disease

M. Giedlin, D. Portnoy, E. Lemmens, 2007, The Journal of Immunology.

Immunotherapy for Liver Metastatic Disease Activation of Immature Hepatic NK Cells As

M. Giedlin, D. Portnoy, E. Lemmens, 2007 .

Induction of tissue-specific autoimmune prostatitis with prostatic acid phosphatase immunization: implications for immunotherapy of prostate cancer.

E. Engleman, L. Fong, D. Brockstedt, 1997, Journal of immunology.

Development of anti-tumor immunity against a non-immunogenic mammary carcinoma through in vivo somatic GM-CSF, IL-2, and HSVtk combination gene therapy.

Y. Chiang, D. Brockstedt, N. Belmar, 2002, Molecular therapy : the journal of the American Society of Gene Therapy.

A Live-Attenuated Listeria Vaccine (ANZ-100) and a Live-Attenuated Listeria Vaccine Expressing Mesothelin (CRS-207) for Advanced Cancers: Phase I Studies of Safety and Immune Induction

E. Jaffee, J. Nemunaitis, P. Illei, 2011, Clinical Cancer Research.

Randomized phase II study of the safety, efficacy, and immune response of GVAX pancreas (with cyclophosphamide) and CRS-207 with or without nivolumab in patients with previously treated metastatic pancreatic adenocarcinoma (STELLAR).

E. Jaffee, T. Crocenzi, K. McDougall, 2016 .

Randomized Phase II study of the safety, efficacy and immune response of GVAX pancreas (with cyclophosphamide) and CRS-207 with or without nivolumab in patients with previously treated metastatic pancreatic adenocarcinoma (STELLAR)

E. Jaffee, T. Crocenzi, K. McDougall, 2015, Journal of Immunotherapy for Cancer.

Phase II, randomized study of GVAX pancreas and CRS-207 immunotherapy in patients with metastatic pancreatic cancer: Clinical update on long term survival and biomarker correlates to overall survival.

E. Jaffee, H. Maecker, D. Le, 2015 .

Novel Piperidinyl-Azetidines as Potent and Selective CCR4 Antagonists Elicit Antitumor Response as Single Agent and in Combination with Checkpoint Inhibitors.

P. Kassner, G. Cutler, M. Zibinsky, 2020, Journal of medicinal chemistry.

Dendritic Cells Injected Via Different Routes Induce Immunity in Cancer Patients1

Edgar G. Engleman, E. Engleman, L. Fong, 2001, The Journal of Immunology.

A Potent and Effective Suicidal Listeria Vaccine Platform

Chen Chen, D. Portnoy, Chris S. Rae, 2019, Infection and Immunity.

Tumor-Specific T Cell Dysfunction Is a Dynamic Antigen-Driven Differentiation Program Initiated Early during Tumorigenesis.

Jeffrey J Delrow, J. Delrow, P. Greenberg, 2016, Immunity.

Interferon-producing killer dendritic cells provide a link between innate and adaptive immunity

L. Lanier, D. Pardoll, M. Stins, 2006, Nature Medicine.

Mice Lacking the Type I Interferon Receptor Are Resistant to Listeria monocytogenes

D. Portnoy, M. O’Riordan, D. Brockstedt, 2004, The Journal of experimental medicine.

EBV+ tumors exploit tumor cell-intrinsic and -extrinsic mechanisms to produce regulatory T cell-recruiting chemokines CCL17 and CCL22

P. Kassner, P. Busson, G. Cutler, 2022, PLoS pathogens.

A Listeria vaccine and depletion of T-regulatory cells activate immunity against early stage pancreatic intraepithelial neoplasms and prolong survival of mice.

A. Maitra, E. Jaffee, L. Coussens, 2014, Gastroenterology.

Killed but metabolically active vaccines.

P. Lauer, D. Brockstedt, T. Dubensky, 2012, Current opinion in biotechnology.

Suppression of Cell-Mediated Immunity following Recognition of Phagosome-Confined Bacteria

D. Portnoy, E. Lemmens, J. Shugart, 2009, PLoS pathogens.

Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients

Mario Roederer, Mark M. Davis, S. Swetter, 1999, Nature Medicine.

Dendritic Cell-Based Xenoantigen Vaccination for Prostate Cancer Immunotherapy1

E. Engleman, L. Fong, G. Strang, 2001, The Journal of Immunology.

Promises and challenges for the development of Listeria monocytogenes-based immunotherapies

D. Brockstedt, T. Dubensky, Thomas W Dubensky, 2008, Expert review of vaccines.

Tumors establish resistance to immunotherapy by regulating Treg recruitment via CCR4

D. Pookot, P. Kassner, G. Cutler, 2020, Journal for ImmunoTherapy of Cancer.

Novel, Selective Inhibitors of USP7 Uncover Multiple Mechanisms of Antitumor Activity In Vitro and In Vivo

D. Pookot, S. Suthram, P. Kassner, 2020, Molecular Cancer Therapeutics.

KBMA Listeria monocytogenes is an effective vector for DC-mediated induction of antitumor immunity.

N. Bhardwaj, M. Škoberne, E. Lemmens, 2008, The Journal of clinical investigation.

Evaluation of Cyclophosphamide/GVAX Pancreas Followed by Listeria-Mesothelin (CRS-207) with or without Nivolumab in Patients with Pancreatic Cancer

Ludmila V. Danilova, E. Jaffee, L. Coussens, 2020, Clinical Cancer Research.

Single-Cell Immune Competency Signatures Associate with Survival in Phase II GVAX and CRS-207 Randomized Studies in Patients with Metastatic Pancreatic Cancer

E. Jaffee, D. Le, Shih-Yu Chen, 2020, Cancer Immunology Research.

Anti-mesothelin vaccine CRS-207 with or without low-dose cyclophosphamide plus chemotherapy as front-line treatment for malignant pleural mesothelioma (MPM)

H. Kindler, S. Antonia, Anish Thomas, 2015, Journal of Immunotherapy for Cancer.

Antimesothelin vaccine CRS-207 plus chemotherapy as front-line treatment for malignant pleural mesothelioma (MPM).

K. McDougall, H. Kindler, S. Antonia, 2014 .

Abstract LB-198: Combination of PEGylated recombinant hyaluronidase PH20 (PEGPH20) with live-attenuated, double-deleted (LADD) Listeria enhances tumor infiltrating CD8+ T cell response and antitumor efficacy in mice

Jisook Lee, B. Blouw, Curtis B. Thompson, 2017 .

SINGLE-CELL IMMUNE COMPETENCY SIGNATURES ASSOCIATE WITH SURVIVAL IN PHASE 2 GVAX AND CRS-207 RANDOMIZED STUDIES IN METASTATIC PANCREATIC CANCER PATIENTS

E. Jaffee, D. Le, Shih-Yu Chen, 2020 .

Abstract 4441: Discovery of potent and selective inhibitors of USP7 with anti-tumor activity in vitro and in vivo

D. Pookot, P. Kassner, G. Cutler, 2019, Molecular and Cellular Biology / Genetics.

A phase 2, randomized trial of GVAX pancreas and CRS-207 immunotherapy versus GVAX alone in patients with metastatic pancreatic adenocarcinoma: Updated results.

E. Jaffee, T. Greten, T. Crocenzi, 2014 .

Simultaneous detection of murine antigen-specific intracellular cytokines and CD107a/CD107b by flow cytometry

H. Maecker, D. Brockstedt, S. Ghanekar, 2007 .